Results 271 to 280 of about 9,600,367 (343)

Impact of Six‐Month Monitoring Compared to Three‐Month Monitoring of Laboratories During Methotrexate Therapy

open access: yesArthritis Care &Research, EarlyView.
Objective To evaluate whether extending the American College of Rheumatology–recommended monitoring interval for complete blood count and liver function tests in patients receiving methotrexate (MTX) affects timely detection of medication‐related toxicity.
Spencer Simko   +4 more
wiley   +1 more source

Employment Trajectories of Patients With Systemic Lupus Erythematosus and Factors Driving Transitions Between States

open access: yesArthritis Care &Research, EarlyView.
Objective Systemic lupus erythematosus (SLE) significantly impacts employment capacity. This study aimed to investigate the impact of burden of disease activity, damage, and treatment on employment outcomes and transitions in patients with SLE. Methods Using data from a single center, we analyzed employment transitions, adjusted mean disease activity ...
Javier Mencia‐Ledo   +4 more
wiley   +1 more source

Incidence, Risk Factors and Management of Adverse Events in Contemporary Real‐World Care of Children with Juvenile Idiopathic Arthritis

open access: yesArthritis Care &Research, Accepted Article.
Objective We describe the frequency, risk factors, severity, and management of actionable and serious adverse events (AAE and SAE) in children with newly diagnosed Juvenile Idiopathic Arthritis (JIA) in Canada. Methods We enrolled patients within 3 months of JIA diagnosis in the Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) Registry,
Bashayer Alnuaimi   +10 more
wiley   +1 more source

Real‐world effectiveness and safety of secukinumab in giant cell arteritis: an Italian multicentre cohort study

open access: yesArthritis Care &Research, Accepted Article.
Objective The objective of this study was to evaluate the real‐world effectiveness and safety of secukinumab in giant cell arteritis (GCA) patients. Methods This multicentre retrospective study included patients with GCA who received secukinumab at 14 Italian centres with at least 6 months of follow‐up.
Luca Iorio   +29 more
wiley   +1 more source

Home - About - Disclaimer - Privacy